Robotic retroperitoneoscopic pancreatic tumor enucleation versus robotic transabdominal pancreatic tumor enucleation: a randomized clinical trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900023755

Enrollment

Unknown

Registered

2019-06-10

Start date

2019-08-01

Completion date

Unknown

Last updated

2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic tail and body benign diseases

Interventions

A:robotic retroperitoneoscopic pancreatic tumor enucleation

B:robotic transabdominal pancreatic tumor enucleation

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Obtain informed consent signed by the patient or his or her legal agent; 2. Compliance with the study plan and follow-up procedure; 3. Aged 18 to 70 years old male and female; 4. No surgical contraindications, able to tolerate radical surgery, ECOG behavioral status score 0-1, life expectancy = 12 weeks, ASA score = 2; 5. Diagnosed as pancreatic body and tail benign diseases preoperatively according to clinical symptoms, imaging examination, tumor markers and other auxiliary examinations and postoperative pathology.

Exclusion criteria

Exclusion criteria: 1. Malignant diseases in pancreatic body and tail; 2. patients with severe cardiopulmonary function, liver and renal function infection; 3.Infection of HCV, HIV, syphilis; 4.Women during pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame
postoperative pancreatic fistula(POPF) rate;	—

Secondary

Measure	Time frame
operative time; postoperative morbidity rate;Hospital stay;Blood loss;	—

Countries

China

Contacts

Public ContactLiu Rong

Chinese People's Liberation Army (PLA) General Hospital

liurong301@126.com+86 010 66937591

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026